LONDON, Nov 18 (Reuters) - The European Medicines Agency
(EMA) intends to conclude the approval process for AstraZeneca's
antibody cocktail to prevent and treat COVID-19 at the
start of next year, the regulator's head of vaccine strategy
said on Thursday.
"Evusheld is one of those products that is under rolling
review, and we will, in the coming weeks, and most likely the
beginning of next year, proceed rapidly towards the conclusion
of the process for marketing authorisation," Marco Cavaleri said
at a media briefing, referring to the brand name of the drug.
(Reporting by Pushkala Aripaka and Alistair Smout; Editing by
Kirsten Donovan)
Astrazeneca (AZN)
